- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07757399
The Therapeutic Effects of Ceylon Cinnamon Supplementation and a Self-Efficacy Educational Program on Glycemic Control, Lipid Profiles, and Pain in Type 2 Diabetes Mellitus With Painful Diabetic Peripheral Neuropathy (Ceylon-EDU-RCT)
The Therapeutic Effects of Ceylon Cinnamon Supplementation and a Self-Efficacy Educational Program on Glycemic Control, Lipid Profiles, and Pain in Type 2 Diabetes Mellitus With Painful Diabetic Peripheral Neuropathy: A Randomized Controlled Trial
Aperçu de l'étude
Statut
Description détaillée
Type 2 diabetes mellitus (T2DM) is a major global health challenge often complicated by diabetic peripheral neuropathy (DPN), which frequently manifests as painful diabetic peripheral neuropathy (PDPN) and severely compromises patients' quality of life. Conventional pharmacological treatments for PDPN often produce limited efficacy and adverse side effects, necessitating safe and effective complementary interventions.
This study is a prospective, three-group, parallel-arm, randomized controlled trial (RCT) designed to investigate the synergistic therapeutic impact of botanical supplementation and behavioral education. A total of 900 eligible adult participants diagnosed with T2DM and PDPN attending clinical healthcare centers will be enrolled and randomly allocated in a 1:1:1 ratio into one of three trial arms:
Control Group (Standard Care, n = 300): Participants receive routine diabetic medical care, standard counseling, and matching placebo capsules administered twice daily for 6 months, without structured educational interventions.
Cinnamon Supplementation Group (n = 300): Participants receive standard routine care alongside pure Ceylon cinnamon (Cinnamomum verum) extract capsules (500 mg orally twice daily with meals, total daily dose: 1,000 mg) for 6 months, combined with a double-blind placebo control for the educational component.
Combined Intervention Group (n = 300): Participants receive the identical daily regimen of 1,000 mg Ceylon cinnamon supplementation for 6 months, integrated with a structured, theory-driven Self-Efficacy-Based Educational Program grounded in Bandura's social cognitive theory. The educational program focuses on self-monitoring of blood glucose (SMBG), medication and supplement adherence, dietary modifications, foot care, and psychological coping strategies for chronic pain.
Primary and Secondary Endpoints:
Evaluations will be conducted at baseline and 6 months post-intervention. Primary outcomes include changes in glycated hemoglobin (HbA1c), fasting blood glucose (FBG), insulin resistance (HOMA-IR), and neuropathic pain severity assessed via the Numeric Rating Scale (NRS). Secondary outcomes include lipid profile biomarkers (Total Cholesterol, Triglycerides, LDL-C, and HDL-C), patient adherence, and safety/adverse event tracking. Statistical analyses will utilize repeated measures ANOVA and mixed-model frameworks to evaluate longitudinal and between-group differences.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Dr. Jawad AHMAD ABU-SHENNAR, Asst.Prof.Dr
- Numéro de téléphone: +962779084560
- E-mail: JAWAD_0799@YAHOO.COM
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 6 months.
- Confirmed diagnosis of painful diabetic peripheral neuropathy (PDPN).
- Age between 18 and 65 years.
- Able to provide written informed consent and willing to comply with the study protocol, supplement intake, and educational sessions.
Exclusion Criteria:
- Type 1 diabetes mellitus or gestational diabetes.
- Severe renal or hepatic impairment.
- Known allergy, hypersensitivity, or contraindication to cinnamon or related botanical products.
- Pregnancy or lactation.
- Concurrent participation in another clinical trial or severe psychiatric/cognitive disorders that hinder study participation.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Matching Placebo Group
Participants receive routine diabetes medical care and matching placebo capsules administered twice daily for 6 months.
|
Placebo capsules identical in appearance, color, and packaging to the cinnamon supplement, taken twice daily for 6 months
|
|
Expérimental: Ceylon Cinnamon Group
Participants receive routine diabetes medical care and pure Ceylon cinnamon (Cinnamomum verum) extract capsules (500 mg orally twice daily, total daily dose: 1,000 mg) for 6 months.
|
Placebo capsules identical in appearance, color, and packaging to the cinnamon supplement, taken twice daily for 6 months
Pure Ceylon cinnamon extract capsules (500 mg per capsule, taken twice daily, total dose 1,000 mg/day for 6 months).
|
|
Expérimental: Combined Intervention Group
Participants receive routine diabetes medical care, 1,000 mg/day Ceylon cinnamon supplementation for 6 months, and a structured Self-Efficacy-Based Educational Program grounded in Bandura's social cognitive theory.
|
Pure Ceylon cinnamon extract capsules (500 mg per capsule, taken twice daily, total dose 1,000 mg/day for 6 months).
A structured educational program grounded in Bandura's social cognitive theory aimed at enhancing self-efficacy and self-management skills evaluated using the Diabetes Self-Efficacy Scale (DSES)in participants with diabetes
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Glycated Hemoglobin (HbA1c)
Délai: Baseline and 6 months
|
Evaluated from venous blood samples to assess glycemic control over the preceding 2 to 3 months, expressed as a percentage (%).
Lower values indicate a better outcome (improved long-term glycemic control).
Normal reference ranges typically fall below 5.7%, with diabetes management targets generally aiming for levels below 7.0%
|
Baseline and 6 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Fasting Blood Glucose (FBG)
Délai: Baseline, 3 months, and 6 months
|
Description: Evaluated from venous blood samples collected following an 8-hour overnight fast, measured in milligrams per deciliter (mg/dL).
Lower values indicate a better outcome (improved fasting glycemic status).
|
Baseline, 3 months, and 6 months
|
|
Change in Lipid Profile Parameters
Délai: Baseline and 6 months
|
Evaluated from venous blood samples collected following an 8-hour overnight fast, measured in milligrams per deciliter (mg/dL). Directionality of improvement varies by component: Total Cholesterol: Lower values indicate a better outcome. Triglycerides: Lower values indicate a better outcome. Low-Density Lipoprotein Cholesterol (LDL-C): Lower values indicate a better outcome. High-Density Lipoprotein Cholesterol (HDL-C): Higher values indicate a better outcome. |
Baseline and 6 months
|
|
Change in Neuropathic Pain Intensity
Délai: Baseline and 6 months (or Baseline, 3 months, and 6 months according to your protocol)
|
Evaluated using the Numerical Rating Scale (NRS).
Participants rate their average neuropathic pain intensity over the preceding 7 days.
Scores range from a minimum value of 0 (no pain) to a maximum value of 10 (worst possible pain).
Higher scores indicate a worse outcome (greater pain intensity).
Pain severity is categorized as mild (1-3), moderate (4-7), or severe (8-10).
|
Baseline and 6 months (or Baseline, 3 months, and 6 months according to your protocol)
|
|
Change in Diabetes Self-Efficacy Score
Délai: Baseline and 6 months
|
Evaluated using the Diabetes Self-Efficacy Scale (DSES).
Item scores range from a minimum value of 1 (not at all confident) to a maximum value of 10 (totally confident), reported as an overall mean score (range 1-10).
Higher scores indicate
|
Baseline and 6 months
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- La douleur
- Manifestations neurologiques
- Maladies du système endocrinien
- Maladies du système nerveux
- Maladies neuromusculaires
- Maladies métaboliques
- Maladies du système nerveux périphérique
- Troubles du métabolisme du glucose
- Diabète sucré
- Conditions pathologiques, signes et symptômes
- Maladies nutritionnelles et métaboliques
- Signes et symptômes
- Diabète sucré, Type 2
- Névralgie
Autres numéros d'identification d'étude
- Educat vs. Ceyl-2026
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .